This is the best week for GU oncologists with the approvals of #belzutifan for post IO/TKI #RCC and #enfortumab -vedotin plus #pembrolizumab for first-line #urothelialcarcinoma . A huge thank you to everyone involved in these groundbreaking works. Excited for our patients!
Different PU Junction and Medial Perirenal Perihilar Masses
These are easy to do percutaneously.
Discussion and video
ctbiopsy.com/case119/
#ctbiopsy #irrad #pelviuretericjunction #PUJ #urothelialcarcinoma #perirenal
Case 119: Pelvi-ureteric junction (PUJ) Mass Biopsy
These are easy to do percutaneously. 63-years old man.
Discussion and video
ctbiopsy.com/case119/
#ctbiopsy #irrad #pelviuretericjunction #PUJ #urothelialcarcinoma
Massive achievement in #BladderCancer #UrothelialCarcinoma .
💡To understand the context of EVP combination, look at this table.
*Data before having maintenance avelumab.
1yOS from 50% ish to 78%. Huge!
authors.elsevier.com/a/1ih5y_ZSJXGt…
A #GU24 roundtable with Drs. Vadim Koshkin MD, Petros Grivas, Karine Tawagi MD, Terry Friedlander, and Guru P. Sonpavde, MD shared their forward-thinking thoughts on the impending direction of #UrothelialCarcinoma treatment. Learn More: buff.ly/3SSi3K1
Full FDA approval for #Erdafitinib for the treatment of pts with locally advanced/metastatic FGFR+ #UrothelialCarcinoma following prior systemic therapy, based on data from THOR/Cohort 1): 36% risk reduction in death in pts with prior PD1/PDL1 inhibition vs chemo J&J Innovative Medicine
Dive into the latest insights from the #UNITE study on targeted agents for advanced #UrothelialCarcinoma with this panel discussion from #GU24 featuring Vadim Koshkin MD, Amanda Nizam, MD, Matt Campbell MD, MS, and Omar Alhalabi, MD. Watch Now: buff.ly/3UWS4Tx
Michael F. Basin, MD presents a comparative study 👏🤯on #urothelialcarcinoma in the bladder and upper tract with FGFR3 mutation. FGFR3mut+ status is more frequent in advanced TUC than in CUB. Patients with CUB FGFR3mut+ have more genomic co-drivers than those with TUC FGFR3mut+.…
Advanced #urothelialcarcinoma #bladdercancer first-line treatment- my thoughts ASCO - customization necessary since one size does not fit all (this is a ‘truism’ for almost anything?) dailynews.ascopubs.org/do/selecting-f…
🎙️ Adjuvant RT is safe and tolerated for #ureteralcancer ‼️OncoAlert
📌Retro Study span: 1998 - 2017 evaluating post 🔪RT for upper tract #urothelialcarcinoma
🥇🎯:OS, LRFS, DFS
📊RESULTS
👉All 👥 completed RT 💪
👉N🚫severe late tox
👉5-/10-y OS, DFS, LRFS rates:…
Delighted to participate in this magnificent mid term conference of #NZUSI on #urothelialcarcinoma at AIIMS Jodhpur as an invited faculty in a panel discussion on complications of #TURBT in such august gathering. Urological Society of India 🇮🇳 Rahul Jena #bladdercancer
Dr Maria Jiang discusses results of the #CheckMate274 study on patients with muscle-invasive #urothelialcarcinoma . See her full analysis here: ow.ly/PHG850RmNFR
Watch all content from our Best of ASCO®️ GU & GI Cancers conference here: ow.ly/8etL50RmNFS
#MedOnc
#TumorBoardTuesday Jon Anker, MD, PhD Matt Galsky Mike Pishvaian GrepMed Brian Rini, MD Petros Grivas Rafee Talukder World Bladder Cancer Patient Coalition Bladder Cancer Advocacy Network Tom Powles Amanda Nizam, MD Shilpa Gupta Ali Khaki Raffaele Colombo Mike Glover Albert Jang, MD Santhosh Ambika Adam Kibel Arun Azad Nick James Toni Choueiri, MD Brian Shuch, MD Some 🗝️takeaways:
- EV+ pembro= new SOC in advanced #urothelialcarcinoma
- Gem/cis + nivo >> gem/cis
- ADCs continue to move forward in tx seq
- Unique AEs:
🔹Hyperglycemia, severe rash
If you learned as much as I did, please retweet and share!
x.com/tumorboardtues…
What a stimulating session on #UrothelialCarcinoma with top experts! Shilpa Gupta Karima Oualla, MD,MSc 🔥 So many insightful discussions and takeaways. Big shoutout to Ashish M. Kamat, MD, MBBS for organizing such an excellent event! #bladderCa #AUA24 IBCG
How to select the correct strategies to personalize the care for advanced #urothelialcarcinoma ?
Join us & discuss with Simon Crabb from ECMC Network Southampton in presence or virtually!
Register for free➡️ow.ly/pMgb50R6xAE
#IUCS24 Giuseppe Banna Ravindran Kanesvaran
🔘 Selecting First-Line Therapy for Metastatic Urothelial Carcinoma: Does ‘One Size Fit All’ or Is Customization Needed?
#UrothelialCarcinoma #bladdercancer
buff.ly/4azxVb0
#MEDIA : The EU Medicines Agency #CHMP issued a positive opinion for our #immunotherapy -chemotherapy combination as a first-line treatment for adult patients with unresectable or metastatic #urothelialcarcinoma . bit.ly/44kQ1eC